Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic Cardiomyopathy
- PMID: 40139877
- PMCID: PMC12013847
- DOI: 10.1016/j.jacbts.2024.12.010
Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic Cardiomyopathy
Abstract
We analyzed the role of pro- and anti-inflammatory eicosanoids in the pathogenesis of arrhythmogenic cardiomyopathy (ACM). Lipidomics revealed reduced levels of anti-inflammatory oxylipins in plasma and increased levels of pro-inflammatory eicosanoids in hearts of Dsg2mut/mut mice, a preclinical model of ACM. Disease features were reversed in vitro in rat ventricular myocytes expressing mutant JUP by the anti-inflammatory epoxyeicosatrienoic acid 14-15-EET, whereas 14,15-EEZE, which antagonizes the 14,15-EET receptor, intensified nuclear accumulation of the desmosomal protein plakoglobin. Inhibition of soluble epoxide hydrolase (sEH), an enzyme that converts anti-inflammatory EETs into polar, less active diols, prevented progression of myocardial injury in Dsg2mut/mut mice and promoted recovery of contractile function. This was associated with reduced myocardial expression of genes involved in innate immune signaling and fewer injurious macrophages expressing CCR2. These results suggest that pro-inflammatory eicosanoids contribute to the pathogenesis of ACM. Inhibition of sEH may be an effective, mechanism-based therapy for ACM patients.
Keywords: lipidomics; oxylipins; pro-inflammatory eicosanoids.
Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Funding Support and Author Disclosures This work was supported by NIH grants R01HL148348 (JES) and 1R01CA276107 (Dr Panigrahy), and by the Credit Unions Kids at Heart and the Carter Joseph Buckley Pediatric Brain Tumor Fund (Dr Panigrahy). Partial support was provided by NIH – NIEHS (RIVER Award), R35 ES030443-01, NIH-NINDS U54 NS127758 (Counter Act Program), and NIH – NIEHS (Superfund Award) P42 ES004699 (all to Dr Hammock). Additional support came from a Washington University in St. Louis Rheumatic Diseases Research Resource-Based Center grant (NIH P30AR073752, Dr Lavine), a National Institutes of Health grant (R35 HL161185, Dr Lavine), a Leducq Foundation Network grant (#20CVD02, Dr Lavine), a Burroughs Welcome Fund grant (1014782, Dr Lavine), a Children’s Discovery Institute of Washington University and St. Louis Children’s Hospital grant (CH-II-2015-462, CH-II-2017-628, PM-LI-2019-829, Dr Lavine), a Foundation of Barnes-Jewish Hospital grant (8038-88, Dr Lavine), and gifts from Washington University School of Medicine (Dr Lavine). Dr Penna was supported by an NIH grant (5Tr32AI007163-44). Additional support came from a British Heart Foundation grant (PG/18/27/33616 to Dr Asimaki). This work was also supported, in part, by the Intramural Research Program of the NIH, National Institute of Environmental Health Sciences (Z01 ES025034 to Dr Zeldin). Dr Yang is a part-time employees of EicOsis Human Health. Dr Hwang is a part-time employees of EicOsis Human Health and is an inventor of a patent related to this study. Dr Lavine is a consultant for Kiniksa, Cytokinetics, Implicit Bioscience, and SUN Pharmaceuticals. Dr Hammock holds patents related to the commercial development of soluble epoxide hydrolase inhibitors for cardiovascular disease; is Chief Scientific Officer of EicOsis Human Health, currently conducting human 1b safety trials of the soluble epoxide hydrolase inhibitor EC5026; and is an inventor of a patent related to this study. Dr Saffitz is a consultant for Implicit Bioscience, Rocket Pharmaceuticals and Rejuvenate Bio and is an inventor of a patent related to this study. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Figures
Update of
-
Inhibition of Soluble Epoxide Hydrolase Reduces Inflammation and Myocardial Injury in Arrhythmogenic Cardiomyopathy.bioRxiv [Preprint]. 2024 Feb 19:2024.02.17.580812. doi: 10.1101/2024.02.17.580812. bioRxiv. 2024. Update in: JACC Basic Transl Sci. 2025 Mar;10(3):367-380. doi: 10.1016/j.jacbts.2024.12.010. PMID: 38463975 Free PMC article. Updated. Preprint.
References
-
- Corrado D., Link M., Calkins H. Arrhythmogenic right ventricular cardiomyopathy. New Eng J Med. 2017;376:61–72. - PubMed
-
- Corrado D., Basso C., Thiene G., et al. Spectrum of clinico-pathologic manifestations of arrhythmogenic right ventricular cardiomyopathy/dysplasia: a multicenter study. J Am Coll Cardiol. 1997;30:1512–1520. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
